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Abstract
To identify susceptibility loci for non-Hodgkin lymphoma (NHL) subtypes, we conducted a three-
stage genome-wide association study. We identified two variants associated with follicular 
lymphoma (FL) in 1,465 FL cases/6,958 controls at 6p21.32 (rs10484561, rs7755224, r2=1.0; 
combined p-values=1.12×10-29, 2.00×10-19), providing further support that MHC genetic variation 
influences FL susceptibility. Confirmatory evidence of a previously reported association was also 
found between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 
(combined p-value=4.24×10-9).
Non-Hodgkin lymphoma (NHL) is a complex group of B- and T-cell neoplasms with 
>300,000 new cases diagnosed worldwide each year (http://www-dep.iarc.fr/globocan/
database.htm). Family and epidemiological studies suggest an important genetic role in the 
etiology of lymphoma1, though the inherited genetic basis of the disease is largely unknown. 
Recently, we conducted a genome-wide association study (GWAS) of three common 
histological subtypes of NHL, follicular lymphoma (FL), chronic lymphocytic leukemia/
small lymphocytic lymphoma (CLL/SLL), and diffuse large B-cell lymphoma (DLBCL), 
using a pooled DNA genotyping strategy2. Due to experimental and technical noise 
associated with pooled DNA GWAS, we conducted a new individual genotyping-based 
study on a larger subset of NHL cases and control using a three-stage GWAS study design 
(Supplementary Table 1, Supplementary Fig. 1).
In Stage 1, we conducted a GWAS using a subset of samples (SF1 study) chosen from a 
larger population-based case-control study of NHL based in the San Francisco Bay Area3. 
After applying quality control metrics (Supplementary Methods), 213 FL, 211 CLL/SLL and 
257 DLBCL cases and 750 controls were included in the final statistical analysis of Stage 1. 
The genome-wide results for FL, CLL/SLL and DLBCL are represented in Supplementary 
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Fig. 2a-c, where overall, 18 SNPs showed unadjusted trend p-values below a 10-5 threshold 
(Supplementary Table 2). The most notable findings were for SNPs associated with FL in 
the major histocompatibility complex (MHC) region on chromosome 6, concentrated around 
two independent peaks at 6p21.33 and 6p21.32 (r2<0.01; Figure 1). The strongest signal in 
6p21.33 is located at the psoriasis susceptibility region 1 (PSORS1) (rs1265086, trend p-
value=3.34×10-6, Supplementary Table 3), where we have previously detected a FL 
susceptibility locus2. The 6p21.32 association peak is located in a region encompassing the 
HLA-DR and HLA-DQ genes. Here, eight SNPs exhibited trend p-values ≤10-4 
(Supplementary Table 3).
In Stage 2, 40 SNPs with the lowest trend p-values for each NHL subtype (Supplementary 
Tables 4-6) were genotyped in two independent population-based case-control studies 
(SCALE4 for FL, Mayo-GEC5 for CLL/SLL) and in a separate sample of 118 DLBCL 
population-based cases and 651 controls (SF1B study) drawn from the same population as 
SF1 (Supplementary Table 1, Supplementary Fig. 1). Seven SNPs were associated with FL 
risk (p<0.05) in the SCALE study (Supplementary Table 7). The two SNPs with the lowest 
p-values, rs7755224 and rs10484561 (allelic p-values=6.30×10-5 and 1.20×10-5) are located 
in the MHC Class II region at 6p21.32. They are in complete linkage disequilibrium (LD) 
(r2=1.0) and lie, respectively, 16kb and 29kb upstream of HLA-DQB1. Four additional SNPs 
were associated with FL in the MHC region at 6p21.33, including the two SNPs, rs6457327 
and rs2517448 (allelic p-values=2.90×10-2 and 3.45×10-2), previously reported in our 
pooled DNA GWAS2.
Two SNPs with trend p-values <0.05 were positively associated with CLL/SLL risk in the 
Mayo-GEC study (rs735665 and rs484458, trend p-values=2.64×10-3 and 6.43×10-3; 
Supplementary Table 7). Located in an intergenic region on 11q24.1, rs735665 was 
previously reported as a risk allele for CLL in a genome scan by Di Bernardo and 
colleagues6. Interestingly, two other SNPs, rs872071 and rs9378805, reported to be highly 
associated with CLL in that study were ranked among the top 100 CLL/SLL SNPs in our 
Stage 1 GWAS (trend p-values = 7.17×10-4 and 1.75×10-4 respectively).
None of the SNPs genotyped in Stage 2 for DLBCL showed evidence of association with 
disease risk (p-value<0.05). Failure to identify associated alleles may be due to the 
heterogeneity of DLBCL as evidenced from gene expression and immunophenotyping 
studies.
In Stage 3, the nine SNPs associated with FL and CLL/SLL risk were genotyped in 873 FL, 
471 CLL/SLL, 916 DLBCL cases and 4,470 controls recruited from six case-control studies 
of European descent participating in the InterLymph Consortium (Supplementary Table 1, 
Supplementary Fig. 1). Again, rs10484561 was associated with increased FL risk across all 
studies, with trend p-values ranging from 2.21×10-2 to 1.40×10-10 (Table 1). The combined 
p-value reached 1.12×10-29 in the meta-analysis of samples from all three stages (combined 
odds ratio [OR]=1.95, 95% confidence interval [CI] 1.72-2.22, Supplementary Table 8, 
Supplementary Fig. 3). No evidence was found of heterogeneity across studies (Cochran's Q 
statistic=5.61, d.f.=7, p-value=0.5857; I2 heterogeneity index=0%). Likewise, rs7755224 
was associated with FL in the meta-analysis from all stages (combined p-value=2.00×10-19, 
Conde et al. Page 2
Nat Genet. Author manuscript; available in PMC 2011 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
OR=2.07, 95% CI 1.76-2.42, Supplementary Table 8, Supplementary Fig. 4) and no 
evidence was found of significant heterogeneity (Q=5.42, d.f.=3, p-value=0.1438; 
I2=44.6%). While the association between rs6457327 and FL was replicated in Stage 2, and 
in three other independent sample sets2, this association was poorly replicated in the smaller 
studies from Stage 3, resulting in a weaker combined p-value (6.64×10-6; OR=0.68, 95% CI 
0.58-0.79, Supplementary Table 8) than previously reported2 (see Supplementary Table 9 
for additional information).
For CLL/SLL, rs735665 exhibited a trend p-value of 3.58×10-4 in Stage 3 and a combined 
p-value of 4.24×10-9 in the meta-analysis of all samples (OR=1.81, 95% CI 1.50-2.20; 
Supplementary Table 8). This finding confirms the previous association of rs735665 with 
CLL risk6, and further supports its role in CLL susceptibility.
To search for additional FL-associated variants that were not genotyped in the HLA-DQB1 
region in Stage 1, we imputed SNP genotypes in a 500kb region centered on rs10484561 
(Figure 1). We identified four SNPs with imputed p-values<10-3 that were in complete LD 
with rs10484561 (D'=1, r2=1 in HapMap-CEU), although none showed stronger signals than 
rs10484561 or rs7755224 (Supplementary Table 10). These SNPs are located in a 100kb 
region of relatively high LD in chromosome 6p21.32 that covers HLA-DQB1 and HLA-
DQA1, and in close proximity to HLA-DRB1. Logistic regression analysis conditional on the 
associated SNPs in the region suggested that none were independent signals (Supplementary 
Table 11), and that a single locus or haplotype in LD with rs10484561/rs7755224 may 
harbor the causal variant(s). Analysis of SNP interactions and preliminary functional 
analyses did not provide further refinement of the signal (Supplementary Methods). 
However, one of the imputed SNPs, rs6457614, reported as a tag SNP for the HLA-
DQB1*0501 allele in European, African and Japanese populations7, suggested that the 
association signal may be driven by this protein variant. To verify our imputation, 
rs6457614 was genotyped in the SF1 study. We found 99% concordance between imputed 
and observed genotypes for rs6457614, which was in strong LD with rs10484561 (D′=0.99, 
r2=0.95 in controls). Because HLA-DRB1*0101 and HLA-DQA1*0101 form the most 
frequent haplotype containing HLA-DQB1*0501 in European American populations8, tag 
SNPs for these two MHC Class II alleles (rs4947332 and rs1794265, respectively)7 also 
were genotyped in SF1. Genotyping results revealed that markers for an extended haplotype 
that includes HLA-DRB1*0101-HLA-DQA1*0101-HLA-DQB1*0501-rs104845561 were 
associated with FL risk (OR=2.07, 95% CI=1.40-3.06, p-value=2.32×10-4).
Several small studies have reported links between MHC Class II alleles and NHL9,10,11, 
with somewhat conflicting results that may be attributable to small sample size, the 
combined analysis of mixed NHL subtypes, and/or differences in ethnic groups being 
analyzed11. In a large pooled study within the InterLymph consortium, the variant allele for 
TNF-308G>A (rs1800629) and a TNF/LTA haplotype located in the MHC Class III region 
were positively associated with DLBCL risk, but no association was found for FL12. 
Further, MHC Class I and II alleles have been evaluated in the context of TNF extended 
haplotypes, which revealed independent positive associations for TNF-308A and HLA-
B*0801 alleles in risk of DLBCL13. These loci are not in LD with rs10484561 in our 
controls (r2=0.014 for rs10484561 and TNF-308A; r2=0.007 and 0.001 for rs10484561 and 
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HLA-B*0801 tag SNPs [rs6457374, rs2844535]7), suggesting that our signal is not driven 
by these MHC Class III and I loci. Importantly, the association found here in the MHC Class 
II region also appears to be independent of the FL susceptibility locus at PSORS12, since the 
LD block at HLA-DRB1-HLA-DQA1-HLA-DQB1 is located 1.43Mb downstream of the 
PSORS1 locus (Figure 1), and the LD measurement between rs6457327 and rs10484561 
(r2<0.01) in our controls and in HapMap-CEU indicates no correlation between these loci. 
Results from conditional logistic regression analysis adjusted for the additive effects of 
rs6457327 in the SF1 study provided additional evidence for an independent role of 
rs10484561 (p-value=3.46×10-5) in FL risk.
In conclusion, we have identified a new FL susceptibility locus at chromosome 6p21.32 with 
combined p-values of 1.12×10-29 and 2.00×10-19 for rs10484561 and rs7755224, 
respectively, providing evidence that genetic variation in the MHC Class II region is 
strongly associated with FL susceptibility. These loci appear to be part of an extended 
haplotype that includes HLA-DRB1*0101-HLA-DQA1*0101-HLA-DQB1*0501. Of note, 
although rs10484561 showed a trend towards association in DLBCL in SF1 (trend p-
value=3.58×10-2), we did not observe markedly significant associations between the MHC 
region with risk of CLL/SLL or DLBCL (Supplementary Fig. 5), which suggests that the 
influence of MHC genetic variation differs by NHL subtype.
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Figure 1. LD and association results for the FL-associated regions in the major 
histocompatibility complex (MHC)
In the main panel, trend p-values (as -log10) are shown for SNPs genotyped in the MHC 
region between positions 30,000Mb and 35,000Mb, where two independent FL-associated 
peaks were found. The first peak, represented by rs6457327 (in yellow), is located at 
6p21.33 in the MHC Class I region. The second independent peak, represented by 
rs10484561 (in green), is located at 6p21.32 in the MHC Class II region. The secondary 
panel shows the SNPs genotyped (in black) and imputed (in red) in Stage 1 in a 500kb 
region centered on rs10484561 at 6p21.32. Imputations were based on data from HapMap 
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Phase II release #22 in CEU population. Figure constructed using the snp.plotter R package 
(http://cbdb.nimh.nih.gov/∼kristin/snp.plotter.html).
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